Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Results Reported From Three NCI-Sponsored Clinical Trials

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, one in patients with melanoma, and one in patients with hormone-refractory prostate cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. All three clinical trials were sponsored by the National Cancer Institute (NCI).

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with locally advanced, recurrent or metastatic hepatocellular cancer was recently completed. In Stage 1 of this two-stage clinical trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. This trial was designed to require at least 1 confirmed partial or complete response out of 15 evaluable patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 7 of the 15 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/21/2014)... consider ways to ease prohibitions on marijuana, the public ... the past century may provide valuable lessons, according to ... legalized marijuana in Colorado and Washington for recreational uses ... to best allow the production, sales and the use ... social ills. , A new study published online by ...
(Date:4/20/2014)... type of cell in the lining of the bladder ... according to researchers at the Stanford University School of ... first to pinpoint the normal cell type that can ... first to show that most bladder cancers and their ... explains why many human bladder cancers recur after therapy. ...
(Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
Breaking Medicine News(10 mins):Health News:Regulating legal marijuana could be guided by lessons from alcohol and tobacco, study says 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2
... Free Support Magazine Helps Individuals and Families Embrace Life to ... N.J., Dec. 5 ConvaTec, a world-leading developer and marketer ... today the launch of ConTact, the new global lifestyle magazine ... with practical advice and feature articles on living a healthy ...
... 5 Empire BlueCross BlueShield today,announced that its employees ... 2008 Associate Giving Campaign. This amount is the,result ... match from the,WellPoint Foundation, Inc. , ... and health services,organizations are especially in need of help," ...
... Call on BCBS and OPM to Restore 2008 Benefits, Extend "Open Season" ... , Affected Patients and Doctors Available to ... , WASHINGTON, Dec. 5 Tick, Tick, Tick! Nearly half ... 8th to either change health care plans or face some costly penalties ...
... SEYMOUR, Tenn., Dec. 5 For many, city ... The usual hustle and bustle is further,glamorized by ... crowds,eager to soak in the joyful atmosphere. However, ... can be an emotionally trying time,filled with expectations ...
... N.J., Dec. 5 World Gourmet Marketing, LLC, creator,of the ... healthier,snack alternatives at the concession stands of the IZOD CENTER. ... when obesity is a national concern, the Nets are recognizing ... offerings,include: World Gourmet,s Sensible Portions Multi Grain Crisps, which are,baked, ...
... 5 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life ... laboratory services, announced today that the Company will release ... on December 17, 2008, at approximately 5:00 p.m. (ET). ... which will be held on December 18, 2008, at ...
Cached Medicine News:Health News:ConvaTec Launches New Lifestyle Magazine for People With an Ostomy 2Health News:Empire BlueCross BlueShield Associates Commit Over $1 Million to Community Organizations in 2008 2Health News:Clock Ticking for Millions of Federal Employees Hoping to Avoid Blue Cross/Blue Shield Benefits Cut 2Health News:Single in the City? How the Holidays Leave the Fabulous Feeling More Like Failures 2Health News:Single in the City? How the Holidays Leave the Fabulous Feeling More Like Failures 3Health News:Nets Provide Fans with Healthy In-Game Snack Option 2Health News:DiagnoCure announces fourth quarter and full year 2008 earnings conference call and webcast 2
Hydrophilic Acrylic Intraocular Lens, AC depth: 4.65....
The STAAR ELASTIC LENS®, is a single piece silicone lens to be placed completely in the capsular bag....
... The Bausch & Lomb SoFlex™ ... Lenses are intended to be ... the visual correction of aphakia ... age or older where a ...
Liberty Three Piece PMMA Lens with UV Absorber....
Medicine Products: